Adding Capecitabine to Cancer Treatment Shows No Benefit for Neuroendocrine Tumors
Large trial finds combination therapy doesn't improve survival or response rates compared to standard treatment alone.
389 articles in this topic
Large trial finds combination therapy doesn't improve survival or response rates compared to standard treatment alone.
Antibody-drug conjugate achieved 21% response rate in heavily pretreated patients with limited options.
Scientists identify TP53 and CYLD mutations that make HPV-positive head and neck cancers more aggressive and treatment-resistant.
Large study finds diabetes drug metformin only slightly slows harmful blood cell mutations, questioning its use for cancer prevention.
New study reveals combining PARP inhibitors with bevacizumab extends progression-free survival in previously treated ovarian cancer patients.
Study identifies blood markers that distinguish long-term survivors from short-term survivors in brain cancer treatment.
Ezabenlimab combined with chemotherapy and radiation therapy offers new treatment approach for stage 3 anal cancer patients.
Researchers report on ezabenlimab treatment combined with chemotherapy and radiation for stage 3 anal cancer patients.
Scientists discover how to reprogram cancer cells into harmless, non-dividing cells by targeting a nuclear enzyme pathway.
Comprehensive review reveals how rapid diagnostic devices could revolutionize neuroblastoma detection in children.
Comprehensive review reveals how mitochondrial dysfunction fuels cancer progression and identifies promising therapeutic opportunities.
Redirecting glucose metabolism during T cell expansion dramatically improves cancer immunotherapy effectiveness.